论文部分内容阅读
骨髓增生异常综合征(MDS)是造血干细胞的克隆性疾病,FAB(法-美-英)协作组分为五型,其中难治性贫血伴原始细胞增多型(RAEB)及转化中的RAEB(RAEB-t)两型的异质性相对较少[1],预后差,属高危MDS。我们采用减低剂量HA(高三尖杉酯碱+阿糖胞苷)方案治疗部分病例,取得较满意疗效,现报导
Myelodysplastic syndrome (MDS) is a clonal disease of hematopoietic stem cells. FAB (French-American-British) collaborative component is divided into five types, of which refractory anemia with primitive erythroblastosis (RAEB) and transformed RAEB RAEB-t) two types of heterogeneity is relatively small [1], the prognosis is poor, is a high-risk MDS. We use the dose reduction HA (homoharringtonine + cytarabine) program for the treatment of some cases, to obtain more satisfactory efficacy, it is reported